An active lifestyle, regardless of vascular risk, may delay the progression of Alzheimer’s disease (AD) by slowing down cognitive decline and neurodegeneration, according to a study presented at the Alzheimer’s Association International Conference (AAIC 2019).
Individuals who identify as sexual or gender minorities (SGM) appear to be at a higher risk of experiencing subjective cognitive decline (SCD) than individuals who identify as cisgender and heterosexual, according to a study presented at the Alzheimer’s Association International Conference (AAIC 2019).
The use of sleep medications may be associated with the risk of dementia or Alzheimer’s disease (AD) in older adults, according to two studies presented at the recent Alzheimer’s Association International Conference (AAIC 2019).
Multisensory dysfunction is tied to an increased risk of developing dementia or Alzheimer’s disease (AD) in older adults, thus underlining the importance of sensory evaluation in this patient subgroup and among those at risk of developing neurodegenerative illnesses, according to studies presented at AAIC 2019.
Biomarkers in the blood may present a new opportunity for developing a simple, noninvasive, and inexpensive screening test for Alzheimer’s disease (AD), according to studies presented at the Alzheimer's Association International Conference (AAIC) 2019.
Sex-specific differences in the way brain regions are connected may influence how tau propagates through the brain and thus, differences in the risk of Alzheimer’s disease between men and women; while participating in the workforce may help stave cognitive decline in women, suggest studies presented at AAIC 2019.
A new combination product (AXS-07), which consists of the triptan rizatriptan and the NSAID* meloxicam, led to rapid and sustained pain relief than treatment with either component alone or placebo in patients with a history of inadequate response to prior acute migraine treatment, according to data from the MOMENTUM study released during the AAN 2020 Meeting.
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.